Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

Cheryl Keech,Gary Albert,Iksung Cho,Andreana Robertson,Patricia Reed,Susan Neal,Joyce S. Plested,MingZhu Zhu,Shane Cloney-Clark,Haixia Zhou,Gale Smith,Nita Patel,Matthew B. Frieman,Robert Haupt,James Logue,Marisa McGrath,Stuart Weston,Pedro A. Piedra,Chinar Desai,Kathleen Callahan,Maggie Lewis,Patricia Price-Abbott,Neil Formica,Vivek Shinde,Louis Fries,Jason D. Lickliter,Paul Griffin,Bethanie E. Wilkinson,Gregory M. Glenn

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

2020

Abstract Background NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins a...

Keywords:

Recombinant DNA
Medicine
2019 20 coronavirus outbreak
Glycoprotein
Coronavirus disease 2019
Virology
severe acute respiratory syndrome coronavirus 2
Spike Protein

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

507

Citations